Abbott is cueing up launch after launch for 2020, while J&J is pinning its device hopes to robotic surgery.
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
The number of biopharma buyouts overall last year did not rise, though more deals were struck in the “sweet spot”, and premiums saw a healthy rise.
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.